Biofarm SA
ROBIO.BX is a pharmaceutical company that generates revenue primarily through the development, production, and sale of pharmaceutical products.
Business. ROBIO.BX is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product-based revenue models typical of the industry. No specific operating segments or geographic breakdowns are provided in the available data. The company is identified by the ticker ROBIO.BX.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ROBIO.BX is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product-based revenue models typical of the industry. No specific operating segments or geographic breakdowns are provided in the available data. The company is identified by the ticker ROBIO.BX.
ROBIO.BX maintains a strong liquidity position, with a current ratio of 4.95, indicating the company has nearly five times more current assets than current liabilities. The company holds RON 111.75 million in cash and equivalents, which is a significant portion of its total assets of RON 636.87 million. The company's liquidity risk is low, supported by its minimal long-term debt of RON 1.19 million and a debt-to-equity ratio of 0.0.
In terms of profitability, ROBIO.BX reports a return on equity (ROE) of 18.35% and a return on assets (ROA) of 15.8%, both of which are strong indicators of efficient capital use and asset management. The company's operating income of RON 105.88 million and net income of RON 100.63 million reflect a healthy margin structure, with gross profit of RON 272.18 million on total revenue of RON 319.33 million.
ROBIO.BX operates as a single-segment entity, with all revenue derived from pharmaceuticals and medical research. The company's geographic exposure is not disclosed in the available data, but its revenue concentration is entirely within its core business. The company's capital expenditures of RON -14.67 million suggest a focus on optimizing existing assets rather than expanding physical infrastructure.
Looking ahead, ROBIO.BX is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the current or next fiscal year. The company's free cash flow of RON 75.26 million and operating cash flow of RON 80.52 million support its ability to fund operations and potentially return value to shareholders. The company's risk assessment indicates low dilution and liquidity risk, with no immediate filing-based flags detected.
Recent events and filings for ROBIO.BX do not include any material changes or disclosures that would significantly impact the company's financial position or strategic direction. The company's analyst price targets are uniformly set at RON 0.85, indicating a consensus on its valuation.
ROBIO.BX's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. The company's minimal long-term debt and strong cash position reduce the likelihood of near-term financial distress. The company's dilution potential is also low, with no signs of imminent share issuance or dilutive events.
- ROBIO.BX has a strong liquidity position with a current ratio of 4.95 and RON 111.75 million in cash and equivalents.
- The company's profitability is robust, with ROE of 18.35% and ROA of 15.8%.
- ROBIO.BX operates as a single-segment entity with no disclosed geographic diversification.
- The company's capital expenditures are minimal, indicating a focus on asset optimization.
- Analysts have set a uniform price target of RON 0.85, suggesting a stable valuation outlook.
- ROBIO.BX presents low liquidity and dilution risk, with no immediate filing-based flags detected.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- ROBIO.BX Market data — financials · 2026-05-29
- Biofarm SA Market data — analyst estimates · 2026-05-29